Targeting menin: a promising therapeutic strategy for susceptible acute leukemia subtypes  

作　　者：Pietro Di Fazio 

机构地区：[1]Department of Visceral,Thoracic and Vascular Surgery,Philipps University of Marburg,Baldingerstrasse,35043,Marburg,Germany

出　　处：《Signal Transduction and Targeted Therapy》2023年第11期5141-5142,共2页信号转导与靶向治疗（英文）

摘　　要：Two recent studies published in Nature focused on the clinical efficacy of the menin inhibitor revumenib(SNDX-5613)in KMT2A(histone-lysine N-methyltransferase 2A)-rearranged or NPM1(Nucleophosmin1)-mutant acute myeloid leukemia.1,2 These studies indicate that menin inhibition and its acquired resistance to long-term exposure to revuminib are key points for future treatment,emphasizing the role of menin as a challenging and promising target for the current treatment of leukemia.

关 键 词：ACUTE clinical THERAPEUTIC 

分 类 号：R733.71[医药卫生—肿瘤]